Europe Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Europe Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Europe Chlorpheniramine Maleate Market Report and Forecast 2024-2032

Europe Chlorpheniramine Maleate Market Outlook

The global chlorpheniramine maleate market size was valued at USD 514.9 million in 2023, with Europe holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 3.50% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.

Key Takeaways

• Recent data revealed that one-third of the people living in the United Kingdom suffer from an allergy, with nearly 49% of Britons reported to suffer from seasonal hay fever. The rising prevalence of allergic conditions in the region is expected to drive market demand.
• One of the major Europe chlorpheniramine maleate market trends is the increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023 , a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis.
• In the European Union, 21.3% of the population was estimated to be aged 65 years or older, according to Eurostat data published in January 2023. Since older adults are more likely to be affected by allergies, the market share for chlorpheniramine maleate products is expected to grow in the forecast period.

Europe Chlorpheniramine Maleate Market Analysis

Chlorpheniramine maleate is a widely popular antihistamine used to relieve symptoms like watery eyes, cough, runny nose, and rash from allergies, among others. The medication is usually taken orally and blocks histamine, a chemical released during an allergic reaction, to manage the associated symptoms. Given its antihistamine properties, over-the-counter chlorpheniramine maleate products are generally used to treat coughs and colds. Various clinical studies have also indicated its effectiveness in managing asthma, plasma cell gingivitis, and chronic urticaria. Thus, the rising clinical application of this antihistamine in treating various disease indications are significantly contributing to the Europe chlorpheniramine maleate market growth.

Allergic conditions are prevalent in Europe, affecting a substantial segment of the population. Recent data revealed that one-third of the people living in the United Kingdom suffer from an allergy, with nearly 49% of Britons reported to suffer from seasonal hay fever. Moreover, it is estimated that half of Europe’s population will be affected by allergies by 2025, which is expected to fuel the demand for allergy medications. Additionally, air pollution triggers allergic rhinitis and other respiratory allergies. For instance, aeroallergens can worsen asthma, which affects around 11% of the population in the United Kingdom . With the rising pollution levels and growing patient base suffering from allergies, the Europe chlorpheniramine maleate market share is poised to witness a surge in the coming years.

One of the major market trends is an increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023 , a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis, a common respiratory illness. The study reported that the chlorpheniramine maleate-based throat spray resulted in significant improvement in symptoms within 3 days of use, reducing the overall time that the patient has symptoms. Such ongoing research initiatives that evaluate the efficacy of the antihistamine treatment in different disease indications are likely to augment the Europe chlorpheniramine maleate market value.

The incidence and severity of allergies tend to rise with age due to the development of chronic conditions and a decline in organ function. In the European Union, 21.3% of the population was estimated to be aged 65 years or older according to Eurostat data published in January 2023. Further, it was stated that the older population in the region is projected to increase significantly in the coming decades. With the rising number of older adults more likely to be affected by allergies, the market share for chlorpheniramine maleate products is expected to grow in the forecast period.

Europe Chlorpheniramine Maleate Market Segmentation  

Market Breakup by Dosage Form

• Tablets
• Syrup
• Eye Drops
• Others

Market Breakup by Application

• Allergy
• Hay Fever (Allergic Rhinitis)
• Common Cold
• Watery Eyes
• Itchy Throat/Skin
• Anaphylactic Shock
• Urticaria

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy

Europe Chlorpheniramine Maleate Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Viatris Inc.
• Bayer AG
• Merck KGaA
• Johnson & Johnson Medical Limited
• GSK plc
• AstraZeneca
• Sanofi
• Cardinal Health
• Novartis AG
• Teva Pharmaceutical Industries Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

• What is the Europe chlorpheniramine maleate market forecast outlook for 2024-2032?

The Europe chlorpheniramine maleate market is expected to be driven by the rising demand for the global chlorpheniramine maleate market, which is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 848.1 million by 2032.

• What are the major factors aiding the Europe chlorpheniramine maleate market demand?

The growing prevalence of allergic conditions and the rising geriatric population in the region are fuelling the demand for the market.

• What are the major Europe chlorpheniramine maleate market trends?

One of the significant trends in the market is the increased emphasis on repurposing chlorpheniramine maleate and related products for new therapeutic indications. In January 2023, a case series published in Cureus Journal highlighted the efficacy of a chlorpheniramine maleate throat spray for managing symptoms associated with COVID-19-induced acute viral pharyngitis.

• What is the market segmentation based on the dosage form?

Based on the dosage form, the market is segmented into tablets, syrup, and eye drops, among others.

• What are the major distribution channels of the market?

Distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.

• What are the applications of the chlorpheniramine maleate?

Major applications of the chlorpheniramine maleate include allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria.

• What is the market segmentation by countries?

The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.

• Who are the key players involved in the Europe chlorpheniramine maleate market?

The key players in the market are Viatris Inc., Bayer AG, Merck KGaA, Johnson & Johnson Medical Limited, GSK plc, AstraZeneca, Sanofi, Cardinal Health, Novartis AG, and Teva Pharmaceutical Industries Ltd.

Meta description

The Europe chlorpheniramine maleate market is poised for growth, driven by the expansion of the global market, which was valued at USD 514.9 million in 2023 and is projected to grow at a CAGR of 5.7% during the forecast period of 2024-2032.

*Please Note:* The report will take 7 business days to complete, after order confirmation.